Syngene International

Syngene International Contract Manufacturing & Development (CDMO) Profile

Syngene is a contract research, development and manufacturing organization (CRDMO) that provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies.

Syngene’s clients are world leaders in their fields, ranging from leading global multinationals to small and medium-sized start-ups, non-profit institutions, academic institutes and government organizations. As a strategic partner to its clients, often working as an extension of their internal scientific teams, Syngene offers innovative, flexible, and efficient approaches to scale up rapidly. This, in turn, enables faster go-to-market and access to patients.Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources. Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics. Clients benefit from a faster, seamless R&D process, while the company can utilize its full breadth of resources.

CDMO Services:
API and/or Ingredients; Finished Dosage Forms (Small Molecule Drugs); Biologics; Cell & Gene Therapy Blow-Fill-Seal (BFS); Cartridges; Inhalers; Liquids; Lyophilized amps/vials; Pre-Filled Syringes (PFS); Semi-solids; Soft Gels; Solids; Sterile Ampoules; Sterile Vials Analytical Development; Cell Line Development; Drug Delivery System; Formulation Development; ICH Stability Testing; Process Development; Protein Synthesis Antibodies; Antibody-drug conjugate (ADC); Fusion Proteins; Recombinants + other Proteins; mRNA Vaccines; Protein Vaccines; Viral Vector Vaccines; Plasmid DNA; Live Biotherapeutic Products

Year Founded: 1993

Head Office: Bangalore, India

Number of Facilities: 3-5

Facility locations: South Asia

Website: Visit the Syngene International website

Linkedin: Connect on Linkedin